knowledge -WSS

knowledge

author：knowledge 2025-09-02 22:06:05 - browse：43469

Principal Deputy FDA Commissioner Janet Woodcock Stefani Reynolds/The New York Times via AP

WASHINGTON — Principal Deputy FDA Commissioner Janet Woodcock will retire early next year from the Food and Drug Administration after helping steer the agency through an historic period of medical advances during nearly four decades in key leadership positions, she confirmed to STAT Thursday.

Woodcock, a doctor with a chemistry degree, joined FDA in 1986 at its biologics center, where she oversaw the approval of the first biotechnology-based treatments for multiple sclerosis and cystic fibrosis. In 1994, she was named director of the drug center, where she played a key role in guiding some of the most impactful changes to the regulation of medicine, according to Trump administration FDA Commissioner Scott Gottlieb.

Woodcock envisioned that antibody drugs would become a backbone of therapy and created a more predictable regulatory path for their review and approval, Gottlieb said. She presided over a major expansion and modernization of the generic drug program, standardizing reviews in a way that allowed the industry to become safer and more robust, and crafted the reform of over-the-counter drug reviews.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： In Memoriam: Notable people who died in 2023
Next article： Will the FTC rein in IQVIA's health data empire?

WSS

Rise in cancer among younger people worries and puzzles doctors

Rise in cancer among younger people worries and puzzles doctors

What to watch for from Zogenix and Amicus clinical trials

Search called off for baby washed away in Pennsylvania flash flood

The haunting brain science of long Covid

CDC Director Mandy Cohen on transparency, trust, and health

explore

knowledge

entertainment

Heart attack and stroke risk calculators need revising

What causes rare myocarditis in young men after Covid vaccines?

DIEP, the 'gold standard' of breast reconstruction, is under threat

Truvian presents data for its desktop blood

Psychedelics group wrestles with new pharma identity

How doctors’ personal politics affect patients

Hollywood unions extend contract negotiations for actors

A new crop of companies is reshaping the health data economy

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

How doctors’ personal politics affect patients

hotspot

Bronny James, LeBron's son, suffers cardiac arrest during basketball practice at USC

'Investigate these claims': UFO transparency at center of House hearing

Rise in cancer among younger people worries and puzzles doctors

UHS says company favors patients whose insurance pays more

Device maker Teleflex to acquire urology company for $600M

Will the FTC rein in IQVIA's health data empire?

knowledge

hotspot

focus

hotspot